A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment

Launched by AHS CANCER CONTROL ALBERTA · Feb 11, 2020

Keywords

ClinConnect Summary

**Trial Summary: Exploring Home Administration of Chemotherapy for Myeloma**

This clinical trial is looking into whether patients with myeloma can safely give themselves a specific chemotherapy treatment called bortezomib at home, rather than needing to come into the hospital or cancer center for each injection. The goal is to see if this approach can be effective and convenient for patients who are stable and capable of self-administering their treatment with some training.

To participate, individuals must be at least 18 years old and have been diagnosed with symptomatic myeloma. They should have received more than four bortezomib injections in a medical setting before and be willing to learn how to give themselves the injection at home. However, those who have had serious side effects from bortezomib or are currently involved in other clinical trials are not eligible. If you decide to join this study, you can expect to receive training on how to safely administer the medication, and all assessments will follow standard care procedures. This trial is currently recruiting participants, and it offers a chance to take part in a potentially beneficial change in how chemotherapy can be given.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients are aged 18 years old or older with a diagnosis of symptomatic myeloma,
• • Stable clinical status as deemed by responsible investigator,
• • Personally (or caregiver) willing and deemed capable to self-administer with teaching,
• • Previously received more than 4 injections of bortezomib within the hospital and/or cancer centre environment,
• • Signed informed consent.
• Exclusion Criteria:
• • Currently participating in clinical trials that includes the use of bortezomib,
• • History of allergic reactions to bortezomib,
• • History of bleeding attributable to bortezomib,
• • History of greater than or equal to grade 3 side effects attributable to bortezomib,
• • Clinically deemed unlikely to be compliant with therapy by responsible investigator,
• • Life expectancy anticipated to be less than 6 months,
• • Deemed geographically inaccessible to receive care.